• 1
    Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835 8.
  • 2
    Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin TJ, Kaplan C et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein. N Engl J Med 1990; 323: 1289 98.
  • 3
    Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemie. N Engl J Med 1995; 333: 1301 7.
  • 4
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383 9.
  • 5
    Sacks FM, Pfeffer MA, Moya LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N Engl J Med 1996; 335: 1001 9.
  • 6
    Mol Mjtm, Gevers Leuven JA, Erkelens DW, Schouten JA, Stalenhoef AFH. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet 1986; ii: 936 9.
  • Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Stanbury JB, Wijngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds.
    The Metabolic Basis of Inherited Diseases, 5th edn. New York: McGraw-Hill, 1983: 672–712.
  • 8
    Kajinami K, Mabuchi H, Koizumi J, Takeda R. Serum apolipoproteins in heterozygous familial hypercholesterolemia. Clin Chem Acta 1992; 211: 93 9.
  • 9
    Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Eur Heart J 1994; 15: 1300 31.
  • 10
    Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR et al. Contrasting effects of unmodified and time-release forms of niacin in lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34: 642.
  • 11
    Bakker-Arkema RG, Best J, Fayyad R, Heinonen TM, Marais AD, Nawrocki JW et al. A brief paper on the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997; 131: 17 23.
  • 12
    Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemie by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis Thrombosis Vasc Biol 1995; 15: 678 82.
  • 13
    Bocan TM, Ferguson E, McNaklly W, Uhlendorf PD, Bak Meuller S, Dehart P et al. Hepatic and non-hepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor-(II-98): comparison with selected HMG-CoA reductase inhibitors. Biochem Biophys Acta 1992; 1123: 133 44.
  • 14
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifugation. Clin Chem 1972; 18: 499 502.
  • 15
    Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128 33.
  • 16
    Goldberg RB, Fless GM, Baker SG, Joffe BI, Getz GS, Scanu AM et al. Abnormalities of high density lipoproteins in homozygous familial hypercholesterolemia. Arteriosclerosis 1984; 4: 472 8.
  • 17
    Black DM. Atrovastatin: a step ahead for HMG-CoA reductase inhibitors . Atherosclerosis 1995; 129: 307 310.